DJ Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech
02-Jul-2021 / 10:36 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
=----------------------------------------------------------------------------------------------------------------------
Aubagne, July 2, 2021
Half-year liquidity contract statement for Sartorius Stedim Biotech
Under the liquidity contract entered into between Sartorius Stedim Biotech and Kepler Cheuvreux, the following
resources appeared on the liquidity account on June 30th 2021:
- 2,374 shares
- EUR 9,177,482.91
- Number of executions on buy side on semester: 659
- Number of executions on sell side on semester: 538
- Traded volume on buy side on semester: 24,109 shares for EUR 8,777,527.71
- Traded volume on sell side on semester: 21,735 shares for EUR 7,961,330.63
As a reminder, the following resources appeared on the liquidity account when the activity started:
- 0 shares
- EUR 10,000,000.00
The liquidity agreement complies with AMF Decision n° 2018-01 dated 2nd July 2018, introducing liquidity agreements on
equity securities as permitted market practice.
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a total solutions
provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically.
Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own
manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies,
Sartorius Stedim Biotech has a global reach. The Group has been annually growing by double digits on average and has
been regularly expanding its portfolio by acquisitions of complementary technologies. In 2020, the company employed
more than 7,500 people, and earned sales revenue of 1,910 million euros.
Contact
Ben Orzelek
Head of Investor Relations
+49 (0)551.308.1668
Ben.orzelek@sartorius.com
Sartorius Stedim Biotech S.A.
Z.I. Les Paluds
Avenue de Jouques, CS 91051
13781 Aubagne Cedex, France
Phone: +33.(0)4.42.84.56.00
Fax: +33.(0)4.42.84.56.19
www.sartorius-stedim.com
Transactions executed by Gilbert Dupont (liquidity provider until March 9, 2021):
Buy side Sell side
Number of Number of Traded volume in Number of Number of Traded volume in
executions shares EUR executions shares EUR
TOTAL 1 0 0,00 10 73 26,218.80
04/01/2021 0 0 0 1 10 3,028
05/01/2021 0 0 0 0 0 0
06/01/2021 0 0 0 0 0 0
07/01/2021 0 0 0 0 0 0
08/01/2021 0 0 0 0 0 0
11/01/2021 0 0 0 0 0 0
12/01/2021 0 0 0 0 0 0
13/01/2021 0 0 0 0 0 0
14/01/2021 0 0 0 0 0 0
15/01/2021 0 0 0 0 0 0
18/01/2021 0 0 0 0 0 0
19/01/2021 0 0 0 0 0 0
20/01/2021 0 0 0 0 0 0
21/01/2021 0 0 0 0 0 0
22/01/2021 0 0 0 0 0 0
25/01/2021 0 0 0 0 0 0
26/01/2021 0 0 0 0 0 0
27/01/2021 0 0 0 0 0 0
28/01/2021 0 0 0 0 0 0
29/01/2021 0 0 0 0 0 0
01/02/2021 0 0 0 2 11 3,854.4
02/02/2021 0 0 0 0 0 0
03/02/2021 0 0 0 1 20 7,600
04/02/2021 0 0 0 0 0 0
05/02/2021 0 0 0 0 0 0
08/02/2021 0 0 0 0 0 0
09/02/2021 0 0 0 0 0 0
10/02/2021 0 0 0 2 15 6,000
11/02/2021 0 0 0 0 0 0
12/02/2021 0 0 0 0 0 0
15/02/2021 0 0 0 0 0 0
16/02/2021 0 0 0 0 0 0
17/02/2021 0 0 0 0 0 0
18/02/2021 0 0 0 0 0 0
19/02/2021 0 0 0 0 0 0
22/02/2021 0 0 0 0 0 0
23/02/2021 0 0 0 0 0 0
24/02/2021 0 0 0 0 0 0
25/02/2021 0 0 0 0 0 0
26/02/2021 0 0 0 0 0 0
01/03/2021 0 0 0 0 0 0
02/03/2021 0 0 0 0 0 0
03/03/2021 0 0 0 0 0 0
04/03/2021 0 0 0 0 0 0
05/03/2021 1 0 0 1 0 0
08/03/2021 0 0 0 0 0 0
09/03/2021 0 0 0 0 0 0
10/03/2021 0 0 0 3 17 5,736.4
11/03/2021 0 0 0 0 0 0
Transactions executed by Kepler Cheuvreux (liquidity provider as of on May 4, 2021):
Buy side Sell side
Number of
Number of Number of Traded volume in executions Number of Traded volume in
executions shares EUR shares EUR
TOTAL 659 24,109 8,777,527.71 538 21,735 7,961,330.63
07/05/2021 26 900 327,780.00 5 450 168,525.00
10/05/2021 109 5,109 1,873,112.67 - - -
11/05/2021 66 1,800 639,198.00 1 100 35,900.00
12/05/2021 10 500 176,700.00 8 503 179,374.83
13/05/2021 10 500 177,000.00 27 1,097 390,970.80
14/05/2021 4 400 143,400.00 14 700 252,098.00
17/05/2021 13 700 250,803.00 14 1,500 542,715.00
18/05/2021 19 700 247,877.00 19 200 71,400.00
19/05/2021 35 900 314,001.00 - - -
20/05/2021 - - - 26 1,000 353,560.00
21/05/2021 2 200 70,520.00 6 100 35,900.00
24/05/2021 3 100 35,200.00 - - -
25/05/2021 2 100 35,400.00 10 300 107,100.00
26/05/2021 11 400 144,200.00 82 3,600 1,307,088.00
27/05/2021 22 1,100 390,126.00 - - -
28/05/2021 14 400 140,520.00 - - -
31/05/2021 3 100 35,500.00 3 100 36,100.00
01/06/2021 5 300 105,900.00 6 200 71,700.00
02/06/2021 48 2,100 727,188.00 13 200 70,900.00
03/06/2021 10 500 170,000.00 1 5 1,735.00
04/06/2021 - - - 16 700 240,121.00
07/06/2021 7 300 102,600.00 7 280 96,860.40
08/06/2021 5 300 106,200.00 38 2,200 781,132.00
09/06/2021 5 200 70,300.00 26 1,100 396,033.00
10/06/2021 10 400 145,400.00 49 1,128 416,062.80
11/06/2021 7 200 73,700.00 12 572 213,710.64
14/06/2021 - - - 26 1,000 379,850.00
15/06/2021 3 200 77,300.00 13 600 232,698.00
16/06/2021 6 200 76,900.00 7 300 116,100.00
17/06/2021 95 2,200 829,004.00 3 100 37,700.00
18/06/2021 9 200 75,500.00 25 900 343,197.00
21/06/2021 34 800 300,784.00 2 100 37,600.00
22/06/2021 3 100 37,490.00 9 500 189,200.00
23/06/2021 2 100 37,800.00 4 118 45,039.42
24/06/2021 1 100 37,800.00 36 1,282 493,659.74
25/06/2021 2 100 38,600.00 9 200 78,500.00
28/06/2021 - - - 21 600 238,800.00
29/06/2021 1 1 402.00 - - -
30/06/2021 57 1,899 763,322.04 - - - ----------------------------------------------------------------------------------------------------------------------- Regulatory filing PDF file File: Half-year liquidity contract statement for Sartorius Stedim Biotech
=-------------------------------------------------------------------------------------------------------
Language: English
Company: Sartorius Stedim Biotech SA
Avenue de Jouques
13781 Aubagne
France
Phone: +33 44 284 5600
E-mail: info@sartorius-stedim.com
Internet: www.sartorius-stedim.com
ISIN: FR0013154002
Euronext Ticker: DIM
AMF Category: Share buyback / Disposal of own shares / Information relating to the liquidity contract
EQS News ID: 1214848
End of Announcement EQS News Service
=------------------------------------------------------------------------------------
1214848 02-Jul-2021 CET/CEST
Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1214848&application_name=news
(END) Dow Jones Newswires
July 02, 2021 04:39 ET (08:39 GMT)
